CCME Global

Why is CCME Global Ltd falling/rising?

As of 05-Sep, CCME Global Ltd's stock price is Rs. 30.80, down 5.0% and has fallen 68.97% over the past month. The stock is in a persistent bearish trend, hitting a 52-week low and experiencing decreased investor participation.

As of 05-Sep, CCME Global Ltd's stock price is falling, currently at Rs. 30.80, which represents a decrease of Rs. 1.62 or 5.0%. The stock has been on a downward trend, having lost 22.52% over the past week and a staggering 68.97% over the past month. Year-to-date, the stock has declined by 63.89%, significantly underperforming the benchmark Sensex, which has only fallen by 10.21% in the same period.<BR><BR>Today, the stock hit a new 52-week low of Rs. 30.80 and has been experiencing consecutive declines for the last 21 days, resulting in a total drop of 65.63% during this time. It opened with a loss of 5% and has not traded above this level throughout the day. Additionally, CCME Global is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent bearish trend.<BR><BR>Investor participation has also decreased, with delivery volume dropping by 32.64% compared to the 5-day average, suggesting a lack of interest from investors. Overall, these factors contribute to the continued decline in the stock price of CCME Global Ltd.

Which are the latest news on CCME Global?

Who are in the management team of CCME Global?

The management team of CCME Global includes Vanitha Nagulavari (Director), Mohammed Baba (Independent Director), Prasada Rao Kalluri (Independent Director), Balakrishna Koppula (Whole-time Director), and M V R L Subrahmanyeswara Rao (Company Secretary & Compliance Officer).

The management team of CCME Global includes the following individuals:<BR><BR>1. **Vanitha Nagulavari** - Director<BR>2. **Mohammed Baba** - Independent Director<BR>3. **Prasada Rao Kalluri** - Independent Director<BR>4. **Balakrishna Koppula** - Whole-time Director<BR>5. **M V R L Subrahmanyeswara Rao** - Company Secretary & Compliance Officer<BR><BR>If you need more information about their roles or the company, feel free to ask!

What does CCME Global do?

CCME Global Ltd operates in the Pharmaceuticals & Biotechnology sector as a Micro Cap company, with a recent net profit of 0 Cr and a market cap of INR 171 Cr. The company has undergone several name changes since its incorporation in 1992, with its latest name being Genesis IBRC India Ltd.

Overview: <BR>CCME Global Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History: <BR>The company was originally incorporated as Fine Plast Polymers Ltd in October 1992, later changing its name to SSK Lifestyles Ltd in October 2014, and finally to Genesis IBRC India Ltd in January 2018. The latest quarterly results reported are for June 2026, showing a net profit of 0 Cr.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 171 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.93 <BR>Return on Equity: -1.77% <BR>Price to Book: 4.49<BR><BR>Contact Details: <BR>Address: Sy Nos 241/2 & 389/2 Dwaraka, Denduluru Village & Mandal West Godavari Andhra Pradesh : 534432 <BR>Email: info@ssklifstyles.com <BR>Website: http://www.genesisbrc.com

Who are the peers of the CCME Global?

CCME Global's peers include Oxygenta Pharma, Brooks Lab., Syschem (India), Achyut Healthcar, Smruthi Organic, Panch.Organics, and Sat Kartar Life, with varying management risks and growth rates. Achyut Healthcar leads in 1-year return at 35.80%, while Brooks Lab. has the lowest at -51.79%.

Peers: The peers of CCME Global are Oxygenta Pharma, Brooks Lab., Syschem (India), Achyut Healthcar, Smruthi Organic, Panch.Organics, and Sat Kartar Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sat Kartar Life, while Average management risk is found at Smruthi Organic and Panch.Organics, and the rest. Below Average management risk is noted for Oxygenta Pharma, Brooks Lab., CCME Global, Syschem (India), and Achyut Healthcar. In terms of Growth, Excellent growth is seen at Sat Kartar Life, Good growth at Syschem (India) and Achyut Healthcar, Average growth at Panch.Organics, and Below Average growth at Oxygenta Pharma, Brooks Lab., CCME Global, and Smruthi Organic. For Capital Structure, Excellent capital structure is noted at Panch.Organics, Good at CCME Global, Syschem (India), Achyut Healthcar, and Smruthi Organic, and Below Average at Brooks Lab. and Oxygenta Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Achyut Healthcar at 35.80%, while the lowest is Brooks Lab. at -51.79%. CCME Global's 1-year return is not available for comparison. Additionally, Syschem (India), Panch.Organics, and Oxygenta Pharma have negative six-month returns.

How big is CCME Global?

As of 31st August, CCME Global Ltd has a market capitalization of 171.00 Cr and reported net sales of 0.04 Cr with a net loss of 0.85 Cr over the latest four quarters. Shareholder's Funds were 9.61 Cr and Total Assets were 12.29 Cr as of March 2018.

As of 31st August, CCME Global Ltd has a market capitalization of 171.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, CCME Global reported net sales of 0.04 Cr. However, it experienced a net loss of 0.85 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2018, where Shareholder's Funds amounted to 9.61 Cr and Total Assets were reported at 12.29 Cr.

When is the next results date for Genesis IBRC India Ltd?

The next results date for Genesis IBRC India Ltd is 14 August 2026.

The next results date for Genesis IBRC India Ltd is scheduled for 14 August 2026.

Should I buy, sell or hold Genesis IBRC India Ltd?

How has been the historical performance of Genesis IBRC?

Genesis IBRC reported a total operating income of 4.34 Cr for the year ending March 2018, resulting in a profit after tax of -0.03 Cr and an earnings per share of -0.03. The company had total liabilities and assets of 12.29 Cr, with no cash flow activity during the period.

Answer:<BR>The historical performance of Genesis IBRC for the year ending March 2018 shows a total operating income of 4.34 Cr, with net sales contributing 4.33 Cr. The total expenditure, excluding depreciation, was 4.16 Cr, leading to an operating profit (PBDIT) of 0.18 Cr. After accounting for interest expenses of 0.03 Cr and depreciation of 0.09 Cr, the profit before tax was recorded at 0.06 Cr. However, the company faced a tax expense of 0.10 Cr, resulting in a profit after tax of -0.03 Cr, which also reflects in the consolidated net profit. The earnings per share (EPS) stood at -0.03, indicating a loss per share. The operating profit margin was 4.2%, while the profit after tax margin was -0.78%. The company had a total liability of 12.29 Cr, with shareholder's funds amounting to 9.61 Cr and total assets also at 12.29 Cr. The cash flow results indicated no cash inflow or outflow during the period.<BR><BR>Breakdown:<BR>Genesis IBRC's financial results for March 2018 reveal a total operating income of 4.34 Cr, primarily driven by net sales of 4.33 Cr. The company managed to maintain a low total expenditure of 4.16 Cr, resulting in an operating profit of 0.18 Cr. However, the profit before tax was only 0.06 Cr, which turned negative after accounting for tax expenses, leading to a profit after tax of -0.03 Cr. This loss per share is reflected in the earnings per share of -0.03. The company's operating profit margin was 4.2%, but the profit after tax margin was negative at -0.78%. On the balance sheet, total liabilities matched total assets at 12.29 Cr, with shareholder's funds at 9.61 Cr. The cash flow statement indicated no activity, with a closing cash balance of 0.00 Cr.

Is Genesis IBRC overvalued or undervalued?

As of September 5, 2025, Genesis IBRC is considered very expensive and overvalued, with high valuation ratios compared to peers and a PEG ratio of 0.00 indicating no expected growth, despite a strong historical return of 281.47% over three years.

As of 5 September 2025, the valuation grade for Genesis IBRC has moved from risky to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios reveal a PE ratio of 14.83, an EV to EBITDA of 14.79, and a Price to Book Value of 10.33, which are notably high compared to industry peers.<BR><BR>In comparison to its peers, Genesis IBRC's valuation metrics are considerably less favorable. For instance, Supreme Industries has a PE ratio of 65.23, while Astral's PE stands at 80.78, both indicating a premium valuation. Additionally, the PEG ratio for Genesis is reported at 0.00, which suggests no expected growth, further reinforcing the overvaluation stance. Despite a strong performance with a 281.47% return over three years, the current valuation metrics suggest that investors should approach Genesis IBRC with caution.

Who are the top shareholders of the Genesis IBRC?

The top shareholders of Genesis IBRC are Diligent Industries Limited with 23.08%, and promoter Arun Kumar P with 4.49%. Individual investors collectively hold 49.31% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Genesis IBRC include Diligent Industries Limited, which holds the highest public shareholding at 23.08%. Additionally, Arun Kumar P is the promoter with the highest individual holding at 4.49%. Individual investors collectively hold 49.31% of the shares. There are no institutional holdings or pledged promoter holdings reported.